 |
Article dans une revue
Reversal of neuromuscular blockade by sugammadex in laparoscopic bariatric surgery: In support of dose reduction
Abstract : Introduction: Sugammadex is the first molecule able to antagonize steroidal muscle relaxants with few adverse effects. Doses are adjusted to body weight and the level of neuromuscular blockade. Sleeve gastrectomy is becoming a very popular form of bariatric surgery. It requires deep muscle relaxation followed by complete and rapid reversal to decrease postoperative and especially post-anaesthetic morbidity. Sugammadex is therefore particularly indicated in this setting. The objective of this study was to evaluate the deep neuromuscular blockade reversal time after administration of various doses of sugammadex (based on real weight or at lower doses). Secondary endpoints were the interval between the sugammadex injection and extubation and transfer from the operating room to the recovery room. We then investigated any complications observed in the recovery room. Materials and methods: This pilot, prospective, observational, clinical practice evaluation study was conducted in the Amiens University Hospital. Neuromuscular blockade was induced by rocuronium. At the end of the operation, deep neuromuscular blockade was reversed by sugammadex at the dose of 4 mg/kg. Results: Sixty-four patients were included: 31 patients received sugammadex at a dosage based on their real weight (RW) and 33 patients received a lower dose (based on ideal weight [IW]). For identical rocuronium doses calculated based on IBW, sugammadex doses were significantly lower in the IW group: 349 (+/- 65) mg versus 508 (+/- 75) mg (P < 0.0001). Despite this dose reduction, neuromuscular blockade reversal took 115 (+/- 69) s in the IW group versus 87 (+/- 40) s in the RW group, but with no significant difference between the two groups (P = 0.08). The intervals between injection of sugammadex and extubation (P = 0.07) and transfer from the operating room to the recovery room (P = 0.68) were also non-significantly longer in the IW group. The mean dose of sugammadex used by anaesthetists in the IW group was 4 mg/kg of ideal weight increased by 35% to 50% (n = 20; 351 +/- 34 mg). No sugammadex adverse effects and no residual neuromuscular blockades were observed. Postoperative nausea and vomiting (PONV) was observed in 19.4% of patients in the real weight group versus 27.3% in the ideal weight group (P = NS). Conclusion: Reversal of deep neuromuscular blockades by sugammadex in obese subjects can be performed at doses of 4 mg/kg of ideal weight plus 35-50% with no clinical consequences and no accentuation of adverse effects. (C) 2015 Societe francaise d'anesthesie et de reanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.
https://hal-u-picardie.archives-ouvertes.fr/hal-03577703
Contributeur : Louise Dessaivre Connectez-vous pour contacter le contributeur
Soumis le : mercredi 16 février 2022 - 17:58:13
Dernière modification le : vendredi 6 mai 2022 - 13:14:11
Contributeur : Louise Dessaivre Connectez-vous pour contacter le contributeur
Soumis le : mercredi 16 février 2022 - 17:58:13
Dernière modification le : vendredi 6 mai 2022 - 13:14:11